predicting resistance to therapy in cll
Published 7 years ago • 229 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
4:14
predicting resistance in cll patients
-
2:34
bruin study update: analysis of the mechanisms of resistance to pirtobrutinib in cll
-
1:20
mechanisms of resistance to targeted therapies in cll
-
1:05
strategies to prevent resistance in cll
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
3:53
sept 2021 what is cll? signs and symptoms of chronic lymphocytic leukaemia
-
3:58
chronic lymphocytic leukemia (cll) - diagnosis and treatment- hematology and oncology series
-
4:05
comparing continuous and fixed duration therapy in cll
-
1:43
biomarker-guided therapy in cll
-
3:50
relevance of current prognostication and prediction markers for cll with new targeted therapies
-
1:33
what to look for in novel cll therapies
-
1:01
cll resistance mechanisms in the era of novel agents
-
1:51
understanding and overcoming resistance mechanisms to novel agents used in cll
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
4:46
prediction and prognostication methods for cll
-
1:36
the utility of mrd for predicting treatment outcomes in patients with cll
-
1:29
the importance of treatment sequencing in cll
-
0:45
key trials in cll and designing a concept for treatment
-
3:09
predicting risk of cll evolution to richter’s syndrome
-
1:13
factors to consider when selecting between continuous and fixed-duration therapy in cll